US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Entero Therapeutics, Inc.

0.4049

+0.00210.52%

Volume:15.48K

Turnover:6.27K

Market Cap:1.93M

PE:-0.07

High:0.4100

Open:0.4000

Low:0.4000

Close:0.4028

Loading ...

Overview Company News Filings

Entero Therapeutics Inc. Conducted Annual Stockholders Meeting

Entero Therapeutics Inc. Granted Extension Until October 8, 2025, to Regain Nasdaq Compliance Amid Delisting Concerns

BRIEF-Entero Therapeutics Inc - Now Offering 15.2 Million Shares Of Common Stock

Entero Therapeutics Inc - NOW Offering 15.2 Mln Shares of Common Stock - SEC Filing

THOMSON REUTERS

BRIEF-Entero Therapeutics Inc Subsidiary Immunogenx Enters Settlement Agreement

Entero Therapeutics Inc - Subsidiary Immunogenx Enters Settlement Agreement - SEC Filing

THOMSON REUTERS

Entero Therapeutics Subsidiary ImmunogenX, LLC Settles Legal Dispute with $7.9 Million Settlement Agreement

Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC

Vicarious Surgical Names Sarah Romano Finance Chief

MT Newswires Live

Entero Therapeutics Names Richard Paolone Interim CEO

MT Newswires Live

Entero Therapeutics names Richard Paolone as interim CEO

Entero Therapeutics Appoints Richard Paolone as CEO

THOMSON REUTERS

Entero Therapeutics Gets $2 Million Revolving Loan, Appoints 3 New Board Members

MT Newswires Live

Entero Therapeutics secures $2M revolving loan, appoints three new directors

Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ENTO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ENTO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENTO\",,,,,undefined,":{"symbol":"ENTO","market":"US","secType":"STK","nameCN":"Entero Therapeutics, Inc.","latestPrice":0.4049,"timestamp":1751896473292,"preClose":0.4028,"halted":0,"volume":15483,"delay":0,"floatShares":4446078,"shares":4765729,"eps":-6.031548,"marketStatus":"Trading","change":0.0021,"latestTime":"07-07 09:54:43 EDT","open":0.4,"high":0.41,"low":0.4,"amount":6270.32020368,"amplitude":0.024826,"askPrice":0.4097,"askSize":100,"bidPrice":0.401,"bidSize":12,"shortable":3,"etf":0,"ttmEps":-6.031548,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1751918400000},"marketStatusCode":2,"adr":0,"listingDate":1476158400000,"exchange":"NASDAQ","adjPreClose":0.4028,"preHourTrading":{"tag":"盘前","latestPrice":0.4,"preClose":0.4028,"latestTime":"09:27 EDT","volume":1170,"amount":468.93834,"timestamp":1751894860015},"postHourTrading":{"tag":"盘后","latestPrice":0.4,"preClose":0.4028,"latestTime":"14:33 EDT","volume":1120,"amount":448.1018,"timestamp":1751567606090},"volumeRatio":1.405454},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENTO\",,,,,undefined,":{"symbol":"ENTO","floatShares":4446078,"roa":"-5.21%","roe":"-33.24%","lyrEps":-5.3277,"volumeRatio":1.405454,"shares":4765729,"dividePrice":0,"high":0.41,"amplitude":0.024826,"preClose":0.4028,"low":0.4,"week52Low":0.185,"pbRate":"-0.37","week52High":1.27,"institutionHeld":0,"latestPrice":0.4049,"committee":-0.785714,"eps":-6.031548,"divideRate":0,"volume":15483,"delay":0,"ttmEps":-6.031548,"open":0.4,"prevYearClose":0.622,"prevWeekClose":0.4028,"prevMonthClose":0.4,"prevQuarterClose":0.4,"fiveDayClose":0.379,"twentyDayClose":0.492,"sixtyDayClose":0.421},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ENTO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548448817","title":"Entero Therapeutics Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2548448817","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548448817?lang=en_us&edition=fundamental","pubTime":"2025-07-03 04:06","pubTimestamp":1751486784,"startTime":"0","endTime":"0","summary":"Entero Therapeutics Inc. held its 2025 Annual Meeting of Stockholders on June 30, 2025. Stockholders elected Edward J. Borkowski, Richard Paolone, Eric Corbett, Manpreet Uppal, and Jack Syage to the board of directors. The appointment of Machias Gini & O'Connell LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. Additionally, the stockholders approved the adjournment of the meeting to address any insufficient proxies for the proposals. All proposals were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entero Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nNDLc9g0Rc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENTO"],"gpt_icon":0},{"id":"2548010450","title":"Entero Therapeutics Inc. Granted Extension Until October 8, 2025, to Regain Nasdaq Compliance Amid Delisting Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2548010450","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548010450?lang=en_us&edition=fundamental","pubTime":"2025-07-01 04:29","pubTimestamp":1751315341,"startTime":"0","endTime":"0","summary":"Entero Therapeutics Inc. has been granted an extension by Nasdaq until October 8, 2025, to regain compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. This follows a letter received on April 11, 2025, indicating non-compliance due to the company's negative stockholders' equity reported in their annual report. If Entero Therapeutics fails to meet the requirements, it may face delisting, but the company can appeal any delisting determination to a Nasdaq Hearing Panel. The company is currently working to meet the conditions set by the extension to maintain its listing status.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entero Therapeutics Inc. published the original content us","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDLbyGWgZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENTO"],"gpt_icon":0},{"id":"2541099800","title":"BRIEF-Entero Therapeutics Inc - Now Offering 15.2 Million Shares Of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2541099800","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541099800?lang=en_us&edition=fundamental","pubTime":"2025-06-06 05:28","pubTimestamp":1749158923,"startTime":"0","endTime":"0","summary":"BRIEF-Entero Therapeutics Inc - Now Offering 15.2 Million Shares Of Common StockJune 5 (Reuters) - Entero Therapeutics Inc ENTO.O:ENTERO THERAPEUTICS INC - NOW OFFERING 15.2 MILLION SHARES OF COMMON STOCK - SEC FILINGFurther company coverage: ENTO.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nFWN3S80Q7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENTO","BK4139"],"gpt_icon":0},{"id":"2541100967","title":"Entero Therapeutics Inc - NOW Offering 15.2 Mln Shares of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2541100967","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541100967?lang=en_us&edition=fundamental","pubTime":"2025-06-06 05:25","pubTimestamp":1749158749,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nFWN3S80Q7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENTO","BK4139"],"gpt_icon":0},{"id":"2535834578","title":"BRIEF-Entero Therapeutics Inc Subsidiary Immunogenx Enters Settlement Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2535834578","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535834578?lang=en_us&edition=fundamental","pubTime":"2025-05-15 05:17","pubTimestamp":1747257465,"startTime":"0","endTime":"0","summary":"BRIEF-Entero Therapeutics Inc Subsidiary Immunogenx Enters Settlement AgreementMay 14  - Entero Therapeutics Inc ENTO.O:ENTERO THERAPEUTICS INC - SUBSIDIARY IMMUNOGENX ENTERS SETTLEMENT AGREEMENT - SEC FILINGENTERO THERAPEUTICS INC - GUARANTORS TO PAY $5.5 MILLION TO MATTRESS LIQUIDATORS - SEC FILINGFurther company coverage: ENTO.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nFWN3RM2YV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENTO"],"gpt_icon":0},{"id":"2535000883","title":"Entero Therapeutics Inc - Subsidiary Immunogenx Enters Settlement Agreement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2535000883","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535000883?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:26","pubTimestamp":1747254368,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nFWN3RM2YV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENTO","BK4139"],"gpt_icon":0},{"id":"2535007075","title":"Entero Therapeutics Subsidiary ImmunogenX, LLC Settles Legal Dispute with $7.9 Million Settlement Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2535007075","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535007075?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:25","pubTimestamp":1747254314,"startTime":"0","endTime":"0","summary":"Entero Therapeutics Inc.'s wholly-owned subsidiary, ImmunogenX, LLC, has recently entered into a notable settlement agreement with Mattress Liquidators Inc., Jack A. Syage, and The Jack A. Syage and Elizabeth T. Syage Revocable Trust. As part of the agreement, the Guarantors have committed to pay $5,500,000 towards settling obligations amounting to approximately $7.9 million owed to the Plaintiff. This payment was completed on April 9, 2025. The agreement also involves the release of Mattress Liquidators Inc.'s security interest in ImmunogenX, LLC. Additionally, both parties have agreed to execute a Stipulation of Dismissal with Prejudice, which will be filed with the District Court in Boulder County, Colorado. This development marks a significant step for ImmunogenX, LLC in resolving its financial obligations.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL73LK38:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENTO"],"gpt_icon":0},{"id":"2522055773","title":"Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2522055773","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522055773?lang=en_us&edition=fundamental","pubTime":"2025-03-25 10:51","pubTimestamp":1742871060,"startTime":"0","endTime":"0","summary":"Boca Raton, Florida-- - Entero Therapeutics, Inc.  , a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal  diseases, announced today that Entero has successfully negotiated and signed a rescission agreement  with 100% of the previous shareholders of ImmunogenX, LLC  in relation to the ImmunogenX Business Combination which was previously announced on December 18, 2023 and ultimately closed on March 14, 2024. The Rescission Agreement and its effects are subject to certain closing conditions, including Entero receiving shareholder approval which must occur on or before June 30, 2025.Entero Therapeutics, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal  diseases. The Company's programs address significant unmet needs in GI health and include: latiglutenase, potentially first-in-class, targeted, oral biotherapeutic for cel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/entero-therapeutics-announces-signing-rescission-025100160.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/entero-therapeutics-announces-signing-rescission-025100160.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ENTO","LENZ","BK4139"],"gpt_icon":0},{"id":"2519839017","title":"Vicarious Surgical Names Sarah Romano Finance Chief","url":"https://stock-news.laohu8.com/highlight/detail?id=2519839017","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519839017?lang=en_us&edition=fundamental","pubTime":"2025-03-13 20:53","pubTimestamp":1741870387,"startTime":"0","endTime":"0","summary":"Vicarious Surgical  said Thursday it has named Sarah Romano as chief financial officer, effective April 1.The company said Romana was most recently the CFO at Entero Therapeutics .Vicarious said in December that then-CFO William Kelly was leaving the company on Jan. 2.Shares of the company were up 3.4% in recent Thursday premarket activity.Price: 9.49, Change: +0.31, Percent Change: +3.38","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENTO","RBOT","BK4082","BK4139"],"gpt_icon":0},{"id":"2511419617","title":"Entero Therapeutics Names Richard Paolone Interim CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2511419617","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511419617?lang=en_us&edition=fundamental","pubTime":"2025-02-15 05:16","pubTimestamp":1739567780,"startTime":"0","endTime":"0","summary":"Entero Therapeutics (ENTO) said Friday it named Richard Paolone as interim chief executive.Paolone is a Toronto-based securities lawyer with experience in corporate finance, securities law, and mergers and acquisitions, Entero said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENTO","BK4139","LENZ"],"gpt_icon":0},{"id":"2511617202","title":"Entero Therapeutics names Richard Paolone as interim CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2511617202","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511617202?lang=en_us&edition=fundamental","pubTime":"2025-02-15 05:06","pubTimestamp":1739567160,"startTime":"0","endTime":"0","summary":"Entero Therapeutics (ENTO) announced that the board of directors has appointed Richard Paolone as the interim CEO of the company. Richard Paolone i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/entero-therapeutics-names-richard-paolone-as-interim-ceo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/entero-therapeutics-names-richard-paolone-as-interim-ceo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ENTO","LENZ"],"gpt_icon":0},{"id":"2511612205","title":"Entero Therapeutics Appoints Richard Paolone as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2511612205","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511612205?lang=en_us&edition=fundamental","pubTime":"2025-02-15 05:00","pubTimestamp":1739566803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nFWN3P5102:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ENTO"],"gpt_icon":0},{"id":"2509793617","title":"Entero Therapeutics Gets $2 Million Revolving Loan, Appoints 3 New Board Members","url":"https://stock-news.laohu8.com/highlight/detail?id=2509793617","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509793617?lang=en_us&edition=fundamental","pubTime":"2025-02-08 04:49","pubTimestamp":1738961376,"startTime":"0","endTime":"0","summary":"Entero Therapeutics  got a $2 million revolving loan and appointed three new board members designated by the undisclosed lender as a condition for the funding.Richard Paolone, Eric Corbett and Manpreet Uppal replaced James Sapirstein, Alastair Riddell and Timothy Ramdeen on the board, the company said Friday in a statement.The board has five members. Sapirstein is chief executive officer of Entero.Price: 0.55, Change: +0.03, Percent Change: +6.54","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENTO","BK4139","LENZ"],"gpt_icon":0},{"id":"2509779920","title":"Entero Therapeutics secures $2M revolving loan, appoints three new directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2509779920","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509779920?lang=en_us&edition=fundamental","pubTime":"2025-02-08 04:40","pubTimestamp":1738960810,"startTime":"0","endTime":"0","summary":"Entero Therapeutics (ENTO) announced that it has secured a $2M revolving loan agreement and subsequently appointed three new members to its Board o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/entero-therapeutics-secures-2m-revolving-loan-appoints-three-new-directors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/entero-therapeutics-secures-2m-revolving-loan-appoints-three-new-directors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ENTO","LENZ"],"gpt_icon":0},{"id":"2509752637","title":"Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members","url":"https://stock-news.laohu8.com/highlight/detail?id=2509752637","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509752637?lang=en_us&edition=fundamental","pubTime":"2025-02-08 04:22","pubTimestamp":1738959742,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nTUABRNJ0J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENTO","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ENTO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"ENTO","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"","actualEps":-0.21},{"market":"US","date":"2025-04-01","symbol":"ENTO","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743480000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-13","symbol":"ENTO","fiscalQuarterEnding":"2024/09","expectedEps":-0.32,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"pre","actualEps":-0.44},{"market":"US","date":"2024-10-21","symbol":"ENTO","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1729483200000,"reportTimeType":"pre","actualEps":-3.37},{"market":"US","date":"2024-05-14","symbol":"ENTO","fiscalQuarterEnding":"2024/03","expectedEps":-2.18,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"post","actualEps":0.38}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ENTO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ENTO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ENTO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ENTO","date":"2025-07-03","current":-0.077135,"percent":0.973282,"low":-1.117599,"twenty":-0.297642,"median":-0.226154,"eighty":-0.108624,"high":-0.072578,"avg":-0.27195,"sd":0.226281,"marketCap":1919635},"quantilePoints":[{"date":"2024-05-24","current":-0.927614,"twenty":-0.970244,"median":-0.940771,"eighty":-0.935508,"marketCap":5711061},{"date":"2024-05-31","current":-0.982588,"twenty":-0.972744,"median":-0.960172,"eighty":-0.939455,"marketCap":6049523},{"date":"2024-06-07","current":-1.013075,"twenty":-1.023528,"median":-0.973994,"eighty":-0.952412,"marketCap":6237226},{"date":"2024-06-14","current":-0.884431,"twenty":-1.015488,"median":-0.963958,"eighty":-0.938798,"marketCap":5445198},{"date":"2024-06-21","current":-0.832169,"twenty":-1.006978,"median":-0.960172,"eighty":-0.845837,"marketCap":5123436},{"date":"2024-06-28","current":-0.482417,"twenty":-0.994783,"median":-0.955468,"eighty":-0.832169,"marketCap":2970108},{"date":"2024-07-05","current":-0.399602,"twenty":-0.982337,"median":-0.939126,"eighty":-0.800812,"marketCap":2460239},{"date":"2024-07-12","current":-0.449251,"twenty":-0.981274,"median":-0.884431,"eighty":-0.46312,"marketCap":2765913},{"date":"2024-07-15","current":-0.438195,"twenty":-0.98093,"median":-0.86031,"eighty":-0.449854,"marketCap":2697848},{"date":"2024-08-02","current":-0.249289,"twenty":-0.980587,"median":-0.836189,"eighty":-0.448648,"marketCap":1534805},{"date":"2024-08-09","current":-0.125604,"twenty":-0.970244,"median":-0.832169,"eighty":-0.414396,"marketCap":773307},{"date":"2024-08-16","current":-0.157414,"twenty":-0.961686,"median":-0.779907,"eighty":-0.330047,"marketCap":969155},{"date":"2024-08-23","current":-0.205764,"twenty":-0.960172,"median":-0.486437,"eighty":-0.218699,"marketCap":1266831},{"date":"2024-08-30","current":-0.220374,"twenty":-0.960172,"median":-0.449251,"eighty":-0.21983,"marketCap":1356784},{"date":"2024-09-06","current":-0.213637,"twenty":-0.954527,"median":-0.438195,"eighty":-0.217273,"marketCap":1315305},{"date":"2024-09-13","current":-0.174376,"twenty":-0.944768,"median":-0.408849,"eighty":-0.212728,"marketCap":1073585},{"date":"2024-09-20","current":-0.17966,"twenty":-0.938798,"median":-0.343415,"eighty":-0.190472,"marketCap":1106118},{"date":"2024-09-27","current":-0.183835,"twenty":-0.931561,"median":-0.293586,"eighty":-0.17966,"marketCap":1131819},{"date":"2024-10-04","current":-0.184112,"twenty":-0.901704,"median":-0.232501,"eighty":-0.177546,"marketCap":1133524},{"date":"2024-10-11","current":-0.212422,"twenty":-0.855486,"median":-0.23118,"eighty":-0.17966,"marketCap":1307822},{"date":"2024-10-18","current":-0.384262,"twenty":-0.833777,"median":-0.240216,"eighty":-0.180833,"marketCap":2365792},{"date":"2024-10-25","current":-0.206516,"twenty":-0.832169,"median":-0.235407,"eighty":-0.181837,"marketCap":2225250},{"date":"2024-10-31","current":-0.184113,"twenty":-0.832169,"median":-0.228802,"eighty":-0.181338,"marketCap":1983856},{"date":"2024-11-08","current":-0.19927,"twenty":-0.832169,"median":-0.221933,"eighty":-0.181763,"marketCap":2147171},{"date":"2024-11-15","current":-0.17096,"twenty":-0.811264,"median":-0.221642,"eighty":-0.181763,"marketCap":1696265},{"date":"2024-11-22","current":-0.198843,"twenty":-0.665751,"median":-0.219397,"eighty":-0.17966,"marketCap":1972922},{"date":"2024-11-29","current":-0.226873,"twenty":-0.493706,"median":-0.220374,"eighty":-0.179959,"marketCap":2251033},{"date":"2024-12-06","current":-0.319107,"twenty":-0.488849,"median":-0.221642,"eighty":-0.181246,"marketCap":3166183},{"date":"2024-12-13","current":-0.300277,"twenty":-0.475985,"median":-0.221933,"eighty":-0.181689,"marketCap":2979350},{"date":"2024-12-20","current":-0.2963,"twenty":-0.450055,"median":-0.224285,"eighty":-0.182121,"marketCap":2939892},{"date":"2024-12-27","current":-0.301858,"twenty":-0.449251,"median":-0.226873,"eighty":-0.182664,"marketCap":2995038},{"date":"2025-01-03","current":-0.310483,"twenty":-0.446839,"median":-0.228802,"eighty":-0.183601,"marketCap":3080611},{"date":"2025-01-10","current":-0.297067,"twenty":-0.441411,"median":-0.231244,"eighty":-0.184001,"marketCap":2947498},{"date":"2025-01-17","current":-0.253034,"twenty":-0.433371,"median":-0.238314,"eighty":-0.184113,"marketCap":2510603},{"date":"2025-01-24","current":-0.240049,"twenty":-0.425331,"median":-0.240216,"eighty":-0.184234,"marketCap":2381769},{"date":"2025-01-31","current":-0.239522,"twenty":-0.410698,"median":-0.23981,"eighty":-0.18505,"marketCap":2376539},{"date":"2025-02-07","current":-0.241966,"twenty":-0.399602,"median":-0.240216,"eighty":-0.186061,"marketCap":2400785},{"date":"2025-02-14","current":-0.241966,"twenty":-0.396044,"median":-0.240133,"eighty":-0.186568,"marketCap":2400785},{"date":"2025-02-21","current":-0.248338,"twenty":-0.389419,"median":-0.241091,"eighty":-0.187797,"marketCap":2464013},{"date":"2025-02-28","current":-0.227256,"twenty":-0.384072,"median":-0.240001,"eighty":-0.19026,"marketCap":2254836},{"date":"2025-03-07","current":-0.268318,"twenty":-0.383235,"median":-0.240133,"eighty":-0.190804,"marketCap":2662256},{"date":"2025-03-14","current":-0.226154,"twenty":-0.375026,"median":-0.240001,"eighty":-0.192454,"marketCap":2243902},{"date":"2025-03-21","current":-0.245367,"twenty":-0.340784,"median":-0.240133,"eighty":-0.19453,"marketCap":2434538},{"date":"2025-03-28","current":-0.25634,"twenty":-0.330047,"median":-0.241966,"eighty":-0.198928,"marketCap":2543406},{"date":"2025-04-04","current":-0.115038,"twenty":-0.328524,"median":-0.240133,"eighty":-0.192454,"marketCap":2077511},{"date":"2025-04-11","current":-0.106349,"twenty":-0.324473,"median":-0.239618,"eighty":-0.186359,"marketCap":1920588},{"date":"2025-04-17","current":-0.100543,"twenty":-0.319107,"median":-0.23957,"eighty":-0.184113,"marketCap":1815742},{"date":"2025-04-25","current":-0.099356,"twenty":-0.316889,"median":-0.239546,"eighty":-0.181985,"marketCap":1794296},{"date":"2025-05-02","current":-0.093629,"twenty":-0.314316,"median":-0.238755,"eighty":-0.17966,"marketCap":1690880},{"date":"2025-05-09","current":-0.105214,"twenty":-0.312399,"median":-0.237341,"eighty":-0.172579,"marketCap":1900096},{"date":"2025-05-16","current":-0.113474,"twenty":-0.310483,"median":-0.235737,"eighty":-0.169092,"marketCap":2049263},{"date":"2025-05-23","current":-0.079663,"twenty":-0.303152,"median":-0.230706,"eighty":-0.15958,"marketCap":1982543},{"date":"2025-05-30","current":-0.078897,"twenty":-0.303152,"median":-0.230107,"eighty":-0.152669,"marketCap":1963480},{"date":"2025-06-06","current":-0.094217,"twenty":-0.302117,"median":-0.229987,"eighty":-0.133949,"marketCap":2344738},{"date":"2025-06-13","current":-0.105515,"twenty":-0.301858,"median":-0.228148,"eighty":-0.125604,"marketCap":2625916},{"date":"2025-06-20","current":-0.092743,"twenty":-0.300909,"median":-0.227424,"eighty":-0.114234,"marketCap":2308042},{"date":"2025-06-27","current":-0.083302,"twenty":-0.298926,"median":-0.226873,"eighty":-0.110666,"marketCap":2073092},{"date":"2025-07-03","current":-0.077135,"twenty":-0.297642,"median":-0.226154,"eighty":-0.108624,"marketCap":1919635}],"updateTime":1751885068253}}}